Close

BIO Board of Directors

In accordance with its Bylaws and Articles of Incorporation, the Biotechnology Innovation Organization (BIO) is governed by its Board of Directors.  The Full BIO Board of Directors is comprised of all the directors sitting on the Section Governing Boards, as described below. 

In addition, there is a Board Executive Committee that consists of the seven Elected Officers of the Organization, the immediate Past Chair of the Organization, the Vice Chairs of each Section's Governing Board, and At-Large Directors selected from the Full Board.

There are four Section Governing Boards organized by industrial sector and policy interest.  They are: (1) the Emerging Companies Section (ECS) Governing Board, (2) the Food & Agriculture (F&A) Section Governing Board, (3) the Health Section Governing Board, and (4) the Industrial & Environmental (I&E) Section Governing Board.  BIO’s four Section Governing Boards are comprised of thought leaders who bring their expertise to bear on major issues affecting their specific area of the biotechnology industry.

From time to time, each Section Governing Board may consider candidates to fill vacancies in accordance with BIO’s Bylaws and their own processes and criteria.  In general, BIO Board candidates should be the CEO or Chairman of the Board of a research and development (R&D) focused biotechnology company, but certain Governing Boards have alternative criteria, especially for larger companies.  To be considered for a BIO Board seat, a candidate typically has this type of affiliation with a BIO member company.  If your organization is not a BIO member, click here to learn more about membership.

BECOME A BIO MEMBER

BIO is committed to fostering workforce development, diversity, and inclusion (WDDI) at BIO and across the biotechnology industry.  To that end, candidates should affirmatively support BIO’s WDDI Principles, and pledge to do her or his part to foster diversity and inclusion among employees, customers, and patients.  BIO’s WDDI Principles can be found at: https://www.bio.org/diversity

If you are interested in nominating yourself or another person to be a candidate and potentially fill a vacancy on the BIO Board, please inquire here to learn more about the BIO Board nomination process:

Inquire about BIO Board Nominations

If you have any questions about the BIO Board of Directors, please contact Peter McHugh at pmchugh@bio.org.

For reference, a diagram of the Board and Committee structure is presented below.

Board and Committee structure

 

Executive Committee

Executive Committee

Jeremy M. Levin, DPhil, MB BChir Board & Health Section Chair
Chairman & CEO, Ovid Therapeutics Inc.
John Maraganore, PhD Immediate Past Chair
Chief Executive Officer, Alnylam Pharmaceuticals, Inc.
Bradford A. Zakes, MBA Treasurer
Chief Executive Officer, Cerevast Therapeutics, Inc
Julie L. Gerberding, MD, MPH Secretary
Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, Merck
Paul J. Hastings Health Section Vice Chair
President & CEO, Nkarta Inc.
Ted W. Love, MD ECS Chair
Chief Executive Officer, Global Blood Therapeutics
Philip W. Miller, PhD Food & Ag Section Chair
Sr. Vice President, Agricultural Global Government Relations, Regulatory Policy, Bayer CropScience, Inc.
Hugh Welsh, JD I&E Section Chair
President, DSM North America
Jill Zullo, PhD I&E Section Vice Chair
Vice President, Bioindustrials NA, Cargill, Inc
Stuart A. Arbuckle
Executive Vice President and Chief Commercial Office, Vertex Pharmaceuticals Incorporated
Ron Cohen, MD
CEO, Acorda Therapeutics, Inc.
Douglas A. Doerfler
President & CEO, MaxCyte, Inc
Rachel K. King
Founder & CEO, GlycoMimetics, Inc.
Richard Pops
Chairman & CEO, Alkermes, Inc.
Christi L. Shaw, MBA
SVP & President of Lilly Bio-Medicines, Eli Lilly and Company
Bill Sibold, MBA
Executive Vice President, Genzyme Corporation, A Sanofi Company
Helen Torley, MRCP
President & CEO, Halozyme Therapeutics, Inc.

Section Governing Boards

Emerging Companies Section Governing Board

Ted W. Love, MD Chair
Chief Executive Officer, Global Blood Therapeutics
Kevin C. Gorman, PhD
CEO, Neurocrine Biosciences, Inc
Scott Koenig, MD, PhD
President & CEO, MacroGenics, Inc
Sandy Macrae, PhD
President & CEO, Sangamo Therapeutics, Inc.
John Maraganore, PhD
Chief Executive Officer, Alnylam Pharmaceuticals, Inc.
Jeffrey D. Marrazzo
Co-Founder & CEO, Spark Therapeutics
Sharon Mates, PhD
Chairman & CEO, Intra-Cellular Therapies, Inc.
Steve J. Mento, PhD
President & CEO, Co-Founder, Conatus Pharmaceuticals, Inc
Julia Owens, PhD
President & CEO, Millendo Therapeutics Inc.
George A. Scangos, PhD
Chief Executive Officer, VIR Biotechnology, Inc.
Nancy Simonian, MD
Chief Executive Officer, Syros Pharmaceuticals
Erika Smith, MBA
Chief Executive Officer, ReNetX Bio
Gil Van Bokkelen, PhD
Chairman & CEO, Athersys, Inc.
Thomas G. Wiggans, MBA
Founder & CEO, Dermira, Inc.

Food & Ag Section Governing Board

Philip W. Miller, PhD Chair
Sr. Vice President, Agricultural Global Government Relations, Regulatory Policy, Bayer CropScience, Inc.
Scott Holmstrom
Senior Director, Global Product Development, Elanco
Dan Meagher
President & CEO, Agrivida, Inc.
Adam Monroe
President, Americas, Novozymes
Eddie J. Sullivan, PhD
President & CEO, SAB Biotherapeutics
Karsten Temme, PhD
CEO & Co-Founder, Pivot Bio, Inc.
Rick Turner
Senior Vice President, Seeds & Traits, BASF Corporation
Sylvia Wulf
CEO, AquaBounty Technologies, Inc.

Health Section Governing Board

Jeremy M. Levin, DPhil, MB BChir Chair
Chairman & CEO, Ovid Therapeutics Inc.
Paul J. Hastings Vice Chair
President & CEO, Nkarta Inc.
John Maraganore, PhD Immediate Past Chair
Chief Executive Officer, Alnylam Pharmaceuticals, Inc.
Helen Torley, MRCP Secretary
President & CEO, Halozyme Therapeutics, Inc.
Steve Albers
Corporate Vice President, Market Access and Public Affairs, Novo Nordisk
Gregg H. Alton, Esq
Executive Vice President, Corporate and Medical Affairs, Gilead Sciences, Inc.
Stuart A. Arbuckle
Executive Vice President and Chief Commercial Office, Vertex Pharmaceuticals Incorporated
Martin Babler
Chief Executive Officer, Principia Biopharma
Jean-Jacques Bienaime
President & CEO, BioMarin Pharmaceutical, Inc.
Fabrice Chouraqui, PhD
President, Novartis Pharmaceuticals Corporation
Ron Cohen, MD
CEO, Acorda Therapeutics, Inc.
Terrie Curran
President, Inflammation and Immunology, Celgene Corporation
Douglas A. Doerfler
President & CEO, MaxCyte, Inc
Mark Enyedy
President & CEO, ImmunoGen, Inc.
Barry Flannelly, MBA, PharmD
Executive Vice President & General Manager US, Incyte Corporation
Julie L. Gerberding, MD, MPH
Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, Merck
Sebastian Guth
President of Pharmaceuticals, Americas Region, Bayer Corporation
Alexander Hardy
Chief Executive Officer, Genentech, A Member of the Roche Group
Chris P. Healey
VP, Public Affairs, Grifols
Rachel K. King
Founder & CEO, GlycoMimetics, Inc.
Scott Koenig, MD, PhD
President & CEO, MacroGenics, Inc
Joseph LaRosa, Esq
Executive Vice President, General Counsel and Secretary, Regeneron Pharmaceuticals, Inc.
John Lepore, MD
SVP, R&D Pipeline, GlaxoSmithKline
Nick Leschly
President & CEO, bluebird bio
Liz Lewis
Chief Counsel, Specialty BUs & R&D; Head, Patient Advocacy, Oncology BU, Takeda Pharmaceuticals
Ted W. Love, MD
Chief Executive Officer, Global Blood Therapeutics
Sandy Macrae, PhD
President & CEO, Sangamo Therapeutics, Inc.
Paige Mahaney, PhD
Global Head of Biotherapeutics Discovery Research and Discovery Research Site Head, Boehringer Ingelheim
Jeffrey D. Marrazzo
Co-Founder & CEO, Spark Therapeutics
Sharon Mates, PhD
Chairman & CEO, Intra-Cellular Therapies, Inc.
Steve J. Mento, PhD
President & CEO, Co-Founder, Conatus Pharmaceuticals, Inc
Kenneth I. Moch
President & CEO, Cognition Therapeutics
Michael M. Morrissey, PhD
President & CEO, Exelixis, Inc.
Michael Narachi, MBA, MS
Chief Executive Officer, CODA Biotherapeutics
William J. Newell, JD
Chief Executive Officer, Sutro Biopharma, Inc
David Nicholson, PhD
EVP & Chief R&D Officer, Allergan
Julia Owens, PhD
President & CEO, Millendo Therapeutics Inc.
John Oyler
CEO & Co-Founder, BeiGene, Ltd.
Richard A. Paulson, MBA
EVP & CEO of Ipsen NA, Ipsen Biopharmaceuticals, Inc.
Adelene Q. Perkins, MBA
Chief Executive Officer, Infinity Pharmaceuticals, Inc.
Richard Pops
Chairman & CEO, Alkermes, Inc.
Shaji Procida
President & COO, Eisai, Inc
Mark Pruzanski, MD
Founder, President & CEO, Intercept Pharmaceuticals, Inc.
Mike Raab
Partner, Ardelyx Inc.
Howard W. Robin
President & CEO, Nektar Therapeutics, Inc.
Michael Ryan, PharmD
SVP, Worldwide Value, Access, Policy & Health Economics & Outcomes Research, Bristol-Myers Squibb Company
Christi L. Shaw, MBA
SVP & President of Lilly Bio-Medicines, Eli Lilly and Company
Bill Sibold, MBA
Executive Vice President, Genzyme Corporation, A Sanofi Company
Nancy Simonian, MD
Chief Executive Officer, Syros Pharmaceuticals
Elaine Sorg
President, U.S. Immunology and Patient Services, AbbVie Inc.
Jennifer Taubert
Worldwide Chairman of Pharmaceuticals, Johnson & Johnson
Mark Timney
Chief Executive Officer, The Medicines Company
Mark Trudeau
President & CEO, Mallinckrodt Pharmaceuticals
Gil Van Bokkelen, PhD
Chairman & CEO, Athersys, Inc.
Charl Van Zyl
Chief Operating Officer, UCB SA
Timothy P. Walbert
Chairman, President & CEO, Horizon Therapeutics plc
Sue Washer, MBA
President & CEO, Applied Genetic Technologies Corporation (AGTC)
H. Thomas Watkins
Chair Emeritus, BIO, Biotechnology Innovation Organization
Thomas G. Wiggans, MBA
Founder & CEO, Dermira, Inc.
Rick E. Winningham
Chief Executive Officer, Theravance Biopharma US, Inc.
John Young
Chief Business Officer, Pfizer Inc.
Bernhardt Zeiher, MD
Chief Medical Officer, Astellas Pharma US, Inc.

Industrial & Environmental Section Governing Board

Hugh Welsh, JD Chair
President, DSM North America
Hugh C. Welsh, JD Vice Chair
President, DSM North America
Jill Zullo, PhD Vice Chair
Vice President, Bioindustrials NA, Cargill, Inc
Doug Berven
Vice President, Corporate Affairs, Poet, LLC
Patrick Gruber, MBA, PhD
Chief Executive Officer, Gevo, Inc
Jennifer Holmgren, MBA, PhD
Chief Executive Officer, LanzaTech
David Kettner
President, Virent, Inc
John G. Melo
Chief Executive Officer, Amyris, Inc.
Anna Rath, JD
President & CEO, Vestaron Corporation
Christophe Schilling, PhD
Chief Executive Officer, Genomatica, Inc
Diane Shanahan
Director, Regulatory Affairs, BASF Enzymes LLC
Alan Shaw, PhD
President and Chief Executive Officer, Calysta
Chris Standlee, JD
Vice President, ICM, Inc
Brian Thome
Chief Executive Officer, Edeniq Inc.
Oliver Walker
Chief Executive Officer, Evolva SA
Robert F. Walsh
Senior Vice President, Intrexon Corporation
Roger Wyse, PhD
Managing Partner, Spruce Capital Partners
Jill Zullo, PhD
Vice President, Bioindustrials NA, Cargill, Inc